Global Markets
Home›Global Markets›Europe›Abivax raises $920 million to fund operations through…
Abivax raises $920 million to fund operations through 2029
CNBC World reports the new funding gives the French biotech enough cash to plan a solo U.S. launch rather than depending on a buyer.
Abivax secured a $920 million cash infusion, strengthening its plan for a U.S. presence rather than relying on a sale to another company, the CEO said in an interview with CNBC World.
The biotech’s latest fundraising round provides sufficient liquidity to finance its operations through 2029.
According to CNBC World, that runway is intended to support the company’s next steps as it prepares for a potential solo U.S. launch.
The update signals a shift in strategy for the French firm, as it positions the new cash to carry it through the coming development and commercialization timeline.